All Interventions

    Exenatide

    Pharmaceuticals
    GLP-1 Receptor Agonists

    Exenatide (Byetta/Bydureon) was the first GLP-1 receptor agonist approved, derived from Gila monster saliva (exendin-4). Available in twice-daily and once-weekly formulations, it remains relevant for specific patient populations.

    Evidence Summary

    7
    / 10Score
    Moderate
    Moderate Evidence

    Exenatide has a mature, two-track evidence base. In type 2 diabetes, the EXSCEL cardiovascular outcomes trial (NEJM, 2017; n=14,752, median 3.2 years) established cardiovascular safety - major adverse cardiovascular events did not differ from placebo (HR 0.91, 95% CI 0.83-1.00; non-inferior for safety, not superior for efficacy) - alongside modest weight loss (about 2-4 kg). The most important recent development is in neurology. GLP-1 receptors are expressed in the brain, and a small 2017 phase 2 trial had suggested exenatide might slow Parkinson's disease (a 3.5-point motor advantage vs placebo). The definitive phase 3 Exenatide-PD3 trial (Lancet, 2025; 194 participants, 96 weeks) did not replicate this: off-medication MDS-UPDRS Part III scores worsened by 5.7 points on exenatide versus 4.5 on placebo (adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47), with no benefit on any secondary measure. Exenatide was safe and well tolerated. Recent meta-analyses are mixed - one 2025 review of 5 RCTs found a small motor benefit (-2.06 points), another found none - so a disease-modifying role for GLP-1 agonists in Parkinson's remains unproven.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Synthetic version of exendin-4, a peptide found in Gila monster venom with 53% homology to human GLP-1. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. Resistant to DPP-4 degradation. GLP-1 receptors are also expressed in neurons, which is the rationale for investigating exenatide as a potential neuroprotective (disease-modifying) agent in Parkinson's and Alzheimer's disease.

    Who Is This For?

    Type 2 diabetes where cost is primary concern. Patients needing postprandial glucose control specifically. Step therapy requirements before newer agents.

    Protocol & Dosing

    Dose

    Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily, 60 min before meals. Bydureon: 2mg once weekly, any time of day regardless of meals.

    Frequency

    Twice daily or weekly injection

    Duration

    Ongoing

    Protocol Summary

    First-generation GLP-1 RA. Twice-daily formulation (Byetta) requires timing with meals. Extended-release (Bydureon) offers weekly convenience. Least potent but most affordable option in the class.

    Interactions & Precautions

    Contraindications

    • Severe renal impairment (CrCl <30)
    • Medullary thyroid carcinoma history
    • MEN2
    • Severe GI disease

    Potential Risks

    • •Injection site reactions with extended-release
    • •Higher immunogenicity than human-analog GLP-1 RAs
    • •Thyroid tumor risk

    Potential Side Effects

    Nausea (more pronounced than newer agents)
    Injection site nodules (extended-release)
    Anti-drug antibody formation
    Dizziness
    Headache

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Consider as cost-effective entry point to GLP-1 therapy. Higher nausea rates than newer agents. Anti-drug antibodies may reduce efficacy over time. Renal dose adjustment needed. Most patients will benefit from upgrading to semaglutide or tirzepatide. On the neurology question: despite promising phase 2 data, the definitive phase 3 Exenatide-PD3 trial (2025) found no disease-modifying benefit in Parkinson's disease. Exenatide is not indicated for neurological conditions, and this remains an area of research rather than practice.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Latest Evidence

    2024-2026: the phase 3 verdict on exenatide and Parkinson's

    Exenatide was the first GLP-1 receptor agonist, and for a decade its most exciting prospect was neurological rather than metabolic. A small 2017 single-centre phase 2 trial (Lancet; 62 patients, 60 weeks) hinted that once-weekly exenatide might slow Parkinson's disease - off-medication motor scores showed a 3.5-point advantage over placebo (p=0.0318). That signal drove a wave of interest in GLP-1 agonists as potential disease-modifying therapies for neurodegeneration.

    The definitive test has now reported. The phase 3 Exenatide-PD3 trial (Lancet, 2025) randomised 194 people with Parkinson's across six UK centres to extended-release exenatide 2 mg once weekly or placebo for 96 weeks. It found no disease-modifying benefit: off-medication MDS-UPDRS Part III scores worsened by 5.7 points on exenatide versus 4.5 on placebo (adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47), with no advantage on any secondary measure - though the drug was safe and well tolerated. Recent meta-analyses are split: a 2025 review of 5 RCTs found a small motor benefit (-2.06 points, 95% CI -4.09 to -0.03) while another found none. The question is not fully closed, but the largest and most rigorous trial to date is clearly negative. In type 2 diabetes, exenatide's established role is unchanged - EXSCEL (NEJM, 2017; 14,752 patients) confirmed cardiovascular safety without superiority.

    Exenatide is approved for type 2 diabetes, not for Parkinson's or any neurological condition; the neurology findings above are research results, most of them negative. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1 therapy with a qualified clinician.

    Exenatide in Parkinson's disease · phase 2 (2017) vs phase 3 (2025)

    Why the phase 3 trial reversed the early optimism

    ExenatidePlaceboDownward bar = improvement

    Lower (more negative) scores mean less motor disability. In the 2017 single-centre phase 2 trial (n=62, 60 weeks) exenatide-treated motor scores improved by 1.0 point while placebo worsened by 2.1 points - an adjusted 3.5-point advantage (p=0.0318). The larger, multicentre phase 3 Exenatide-PD3 trial (n=194, 96 weeks) did not replicate this: both groups worsened similarly (exenatide +5.7 vs placebo +4.5; adjusted difference 0.92 points, 95% CI -1.56 to 3.39; p=0.47). Sources: Athauda et al., Lancet (2017) and Vijiaratnam et al., Lancet (2025). Exenatide is not approved for Parkinson's disease. Educational summary of published research, not a treatment claim.

    Key references: Exenatide once a week versus placebo as a potential disease-modifying treatment for Parkinson's disease (Exenatide-PD3) - The Lancet (2025) · Exenatide once weekly versus placebo in Parkinson's disease: a phase 2 randomised controlled trial - The Lancet (2017) · GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis - Therapeutic Advances in Neurological Disorders (2025) · Evaluating the neuroprotective effect of GLP-1 receptor agonists in Parkinson's disease: a systematic review & meta-analysis - Neurological Sciences (2025) · Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL) - New England Journal of Medicine (2017)

    Cost & Access

    Cost Range

    $$

    Accessibility

    Prescription Required

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation